Objectives-To investigate observed stage distributions at first and repeat screenings. To compare the observed outcomes with expected values based on simulation modelling, varying the assumptions about the natural history of the disease. Methods-An overview is made of observed data on stage distribution at first and repeat screenings and the diVerence between those distributions is summarised in a Gini coeYcient. Four possible explanations for the observations are considered, two of these are worked out as Miscan simulation models, and the outcomes are compared with observations. Results-Often the reported stage distributions at repeat screenings are not or only slightly more favourable than at first screenings and, in the ones that are more favourable, the diVerence is relatively small. If, in the Miscan model, it is assumed that there is no correlation between the duration of preclinical breast cancer in consecutive tumour size categories and that there is a strong influence of latent cancers, it is not possible to reproduce the observed outcomes. Conclusions-The two modelled explanations are not suYcient. Decreasing sensitivity seems an unlikely explanation for the discrepancy in many screening programmes. The possibility that the observations may be explained because false reassurance has been given should be seriously considered and investigated. (J Med Screen 1999;6:132-138) 
The performance of cancer screening programmes can be measured by the detection rates-that is, numbers of breast cancers detected per 1000 women screened, and stage distributions in first and subsequent screening rounds and by the incidence and stage distribution of interval cancers compared with a situation without screening. The stage distribution of cancers detected in the first screening round, as a consequence of earlier detection, is expected to be more favourable than that of clinically diagnosed cancers. Because most prevalent cancers are removed from the screened population at the first round, subsequent rounds will only detect cancers that have developed during the screening interval. If the screening interval is suYciently short, detection rates in subsequent rounds will be much lower than in the first round, and the stage distribution is expected to be more favourable than in the first round. In breast cancer screening programmes, detection rates in subsequent rounds have indeed been found to be much lower than in the first round, but the expected concomitant improvement in stage distribution is often small or even absent.
This article investigates the stage distribution of breast cancers detected at repeat screenings compared with first screenings as reported in the literature, using a simple summary measure for a diVerence in stage distribution. The observed outcomes are compared with expected values based on simulation modelling. Four possible explanations for the diVerence between observed and expected values are suggested. The possibilities of further investigation are considered for each.
Methods
Observed data were derived from publications on several breast cancer screening projects, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] summarised in table 1. Some reports split up screen detected cancers by first and repeat screenings, others by first and subsequent rounds, where a subsequent round contains some first screenings of women who were not screened at the first round of invitations.
DiVerent categorisation of size distributions complicates comparison, therefore we summarised the diVerence in size distribution between first and repeat screening by a single valuethe Gini coeYcient. This coeYcient was originally intended to measure inequality of income in a population. 20 The Gini coeYcient G is given by:
where p i and q i denote the proportion of cancers in tumour size category i for first and subsequent screenings respectively, are the corresponding cumulative proportions, and N is the number of size categories. Figure 1 illustrates the calculation of this coeYcient for two screening projects. The cumulative distribution of tumour sizes is given for first screenings of cancers on the x axis and for subsequent screenings on the y axis. The more favourable the size distribution of repeat screenings is relative to the first screening, the higher the graph will be in the figure. The Gini coeYcient is the area between the graph and Inversion >10  mm  Round 1  118  16  43  41  Round 2  22 months  58  21  48  31  Round 3  20 months  46  15  46  39  Two the diagonal multiplied by two, the area below the diagonal is counted as negative. When both size distributions are equal, the Gini coefficient is 0. Increasingly favourable size distributions of repeat screenings relative to first screenings are reflected in higher Gini coeYcients. Figure 1 shows the diagonal, which represents equal stage distribution, and two extreme cases of a diVerence between size distribution at first and repeat screenings.
The 95% confidence intervals for the Gini coeYcients were estimated by the bootstrap method. 21 This method ignores any dependency of stage distribution at first and repeat screenings, but we expect that the influence of that on the variability estimate is negligible.
The computer simulation package Miscan for breast cancer screening evaluation is used for generating expected values for stage distribution at first and repeat screenings. 22 23 Miscan incorporates the natural history of the disease, the epidemiology, the design of the screening programme, and the performance of screening. 24 The natural history of breast cancer is modelled as a progression through a number of states. A life history starts with "no breast cancer" before the onset of preclinical screen detectable disease. There is one preinvasive state-ductal carcinoma in situ (DCIS), and four invasive states in the model, according to the T status of TNM classification (T1a, T1b, T1c, T2+).
In the basic model used in this paper the duration in the diVerent states follows an exponential distribution. Durations of subsequent disease states are 100% correlated so that the duration of the total preclinical screen detectable period is also approximately exponentially distributed. The transition to the clinically diagnosed states (with the same subdivision) is governed by the age-specific incidence rates and the stage distribution in a situation without screening. When cancer is detected early, women will enter the screen detected states (again with the same subdivision). Assumptions about the mean duration by age of the screen detectable preclinical states of breast cancer and the sensitivity of screening were validated using data from the Dutch screening projects in Nijmegen and Utrecht. 22 The mean duration of the preclinical screen detectable period increases with age from 1.8 years at age 35 to 6.2 years at age 70. At age 60 the mean duration times for the diVerent preclinical screen detectable disease states are 5.2 years for DCIS, 0.14 years for T1a, 0.72 years for T1b, 1.49 years for T1c, and 1.12 years for T2+. The sensitivity of mammographic screening assumed for the diVerent disease states is 40% for DCIS, 65% for T1a, 80% for T1b, 90% for T1c, and 95% for T2+.
Three variants of this basic model are considered in this paper.
Variant I assumes that there is no correlation between the duration of consecutive disease states of a cancer. To maintain the same variance of the total preclinical period as in the basic model, model variant I assumes also that the duration in one disease state has a greater variance than in the basic model: a Weibull distribution with shape 0.6. This means that a relatively large proportion of cancers have a very short dwelling time in a particular disease state. For example, in an exponential distribution 5% of the cancers have a dwelling time of less than 5% of the average dwelling time, whereas for a Weibull distribution with shape 0.6 that fraction of fast growing cancers is not 5% but 15%.
Variant II assumes that tumours that will be diagnosed in a situation without screening in a later stage, have a faster growth rate than cancers which are clinically diagnosed in an earlier stage. In model variant II the duration in subsequent disease states is chosen such that cancers diagnosed as T2+ grow twice as fast as those diagnosed as T1c, while cancers diagnosed as T1c in their turn grow twice as fast as those diagnosed as T1a or T1b. The prevalence of each disease state is chosen to equal that in the basic model. This means that of those cancers that are clinically diagnosed as at most T1b, the average duration in T1a at age 60 is 0.34 years and in T1b 1.68 years; of those that are clinically diagnosed as T1c, the duration in T1a is 0.17 years, in T1b 0.84 years, and in T1c 2.18 years; and of those that are clinically diagnosed as T2+, duration in T1a is 0.09 years, in T1b 0.42 years, in T1c 1.09 years, while the duration in T2+ of course does not change (1.12 years) because they are all clinically diagnosed as T2+.
Variant III combines the adjustments to the basic model of both variants I and II by assuming no correlation between consecutive disease states. This is compensated for by a greater variance for each disease state than in the basic model: a Weibull distribution with shape 0.7 (slightly larger than in variant I) and the same average durations of disease states as in variant II. The diVerences between these model variants do not aVect the stage distribution in a situation without screening. Table 1 provides an overview of available data on stage distribution by tumour size at first and repeat screenings. The first column of table 1 indicates whether the data concern initial versus subsequent screenings or first versus repeat screening rounds, where the repeat screening rounds can contain some first screenings. Figure 2 summarises these data by the Gini coeYcients. The Gini coeYcients indicate clearly that for most screening projects, stage distribution at repeat screenings is not much better than at first screenings, and often even worse.
Results
The two county study shows a clearly more favourable tumour size distribution at repeat screenings than at first screenings. 2 3 9 10 The trials in Malmo 1 and Stockholm 5 report similar, diVerences. The two reports from the Edinburgh trial do not show unequivocally whether stage distribution is more favourable at first than at repeat screenings. 7 8 Also, screening projects in Italy, 16 Germany, 11 Finland, 15 California, 14 and in Spain 17 do not show a more favourable stage distribution at repeat screening than at first screenings.
Only from the HIP trial 25 and from projects in Uppsala, 12 the UK, 18 and Ontario 19 are there reports of a substantially better stage distribution at repeat screenings in comparison with first screenings. In Uppsala there was an important increase in screening performance from the second screening round onward, which is illustrated by the fact that the detection rates in the first and second round of screening are equal. This explains why relatively few small tumours were found at first screenings.
There is no apparent correlation between screening interval and diVerence between stage distribution at first and repeat screenings, whereas one would expect that a longer screening interval would lead to a worse stage distribution at repeat screenings.
In summary, of the 16 screening projects from which data have been studied here, 10 show a better stage distribution by tumour size at repeat screenings, five show a worse distribution, and from one trial, one report shows a better and another shows a worse distribution. Table 2 gives the expectations from the Miscan model for the Dutch national breast cancer screening programme. The basic model clearly expects a much more favourable stage distribution at repeat screening than at first screenings than is observed. The model predicts a Gini coeYcient of 13.0%, whereas 1.2% is observed with a 95% confidence interval of -4.6% to 7.0%. Model expectations for other screening projects would be very similar to the one for the Dutch programme. DiVerences in model expectations would be due to diVerences in screening interval and ages of screened women.
Model variant I (without correlation between durations of subsequent disease states) shows a substantially less favourable expected stage distribution at repeat screening than the basic model while the distribution at first screening is very similar. The Gini coeYcient is 8.0%.
Model variant II (where cancers that are diagnosed in later stages have a higher growth rate) shows similar stage distributions as variant I. The Gini coeYcient is 9.0%.
The combined eVects of adjustments from model variants I and II as described by model variant III further worsen the stage distribution at repeat screening, leading to a Gini coeYcient of 4.0%.
The 
Discussion
The observed overall similarity of stage distribution at first screenings and repeat screenings is diVerent than expected. We have tried to quantify this expectation by using the model that was validated against all data from the Nijmegen and Utrecht screening projects. Most observed Gini coeYcients fall far below the expected 13%. We can conceive of four possible explanations for this discrepancy:
The basic model assumes a large variance in rate of development of screen detectable preclinical cancer: the time spent between becoming screen detectable and clinical diagnosis follows an exponential distribution. However, given a certain duration in preclinical cancer for an individual, the proportion of time spent in each of the diVerent preclinical disease states is fixed. This is clearly a simplification. When still assuming exponential distribution of the total screen detectable period, but no correlation between subsequent preclinical disease states, the time spent in one preclinical disease state will have a more than exponential variance. Such higher variance in duration in earlier disease states will lead to a larger proportion of cancers having grown into a larger state during the interval between screenings, thus to a less favourable stage distribution at repeat screenings. Therefore, instead of the 100% correlation between duration in preclinical disease states as in the basic model, model variant I assumes the other extreme: no correlation. This model leads to an expected Gini coeYcient of 8%, which is still higher than most observed Gini coeYcients.
The correlation between duration periods, as discussed in the previous paragraphs, cannot actually be observed because it requires more than two observations of the disease state during the preclinical development of the cancer. Further research therefore is necessarily limited to theoretical approaches. Perhaps this theoretical approach in the future will lead to hypotheses that can be tested.
LATENT CANCERS
Another explanation for the fact that observed Gini coeYcients fall far below the expected 13% is the presence of latent cancers, which are much more prevalent at first screenings than at repeat screenings. Latent cancers may be cancers that can be detected by screening, but which would never be clinically diagnosed in a situation without screening, or they are cancers with a very long preclinical screen detectable period. The first of these two groups would result in a non-transient increase in incidence due to screening. Such an increase is not observed (therefore is at most small) and assuming an exponential distribution of the preclinical screen detectable period as in the basic model accurately predicts observed temporary changes in incidence. 26 The eVect of latent cancers which is already in the basic model can be further increased by assuming a correlation between duration of preclinical disease and stage at clinical diagnosis.
If fast growing cancers are, on average, clinically diagnosed in a later stage than slow growing tumours, then the stage distribution at repeat screening is expected to be worse than in the basic model.
We do not know of any attempt to measure a correlation between growth rate and stage at diagnosis outside screening. However we think that the assumed ratio of growth rates of 1:1:2:4 for cancers that will be diagnosed as T1a, T1b, T1c, or T2+ as in model variant II represents a correlation at the high end of the plausible range. The expected Gini coeYcient of 9% is again higher than most observed Gini coeYcients. Assuming a higher correlation would imply extremely short dwelling times in disease stages preceding the stage in which the cancer is diagnosed without screening, thus a low probability of being detected at screening in an earlier stage than if there were no screening. This does not agree with the fact that the stage distribution of screen detected cancers is generally much better than that of clinically diagnosed cancers.
It is possible to investigate this correlation in studies such as those by Peer et al 27 or Brekelmans et al. 28 A correlation between growth rate and tumour size at diagnosis can be determined from the size at diagnosis outside screening and the apparent size of the tumour as it appears on one previous mammogram. Obviously, clinically diagnosed cancers that can be seen on a previous mammogram will form a selected sample, but this does not necessarily invalidate the test for correlation between growth rate and stage at diagnosis.
Even the combination of the two previously described assumed extreme model variants into model variant III, with a Gini coeYcient of 4%, still leads to an expected stage distribution at repeat screenings that is more favourable than at first screenings.
FALSE REASSURANCE
A negative screening result may induce false reassurance in a woman, who may postpone a visit to the doctor for a lump she may feel in her breast, and in the doctor, who may postpone further diagnostic tests. Such a delay by the patient or doctor may lead to a later diagnosis of interval cancers and to detection of cancers at repeat screenings that otherwise would have been diagnosed earlier as an interval cancer. For this article, only the last possibility is relevant because it influences stage distribution at repeat screenings. The stage distribution of interval cancers is less favourable than that of screen detected cancers. A delay in the detection of such cancers up to the moment of a next screening will thus worsen the stage distribution in subsequent screening rounds. The current Miscan model cannot model false reassurance.
Delay in diagnosis of breast cancer has been studied earlier, [29] [30] [31] particularly its unfavourable eVect on prognosis. [32] [33] [34] The influence on this delay of a negative finding at a preceding screening round has been reported earlier, 35 but still urgently needs to be investigated empirically.
DECREASING SENSITIVITY
The Dutch population screening programme uses double view mammography at first screenings and single view at repeat screenings. Also, it is alleged that there is a pressure on the programme to increase the number of mammographies carried out per screening unit, which might have led to a decreased quality of work since the start of the programme. These two factors may result in a lower sensitivity in repeat screenings, particularly for smaller cancers, and therefore to a less favourable stage distribution. However, it is not plausible that these eVects have occurred in so many screening projects all over the world.
It is possible to investigate whether first and repeat mammograms have the same technical quality, are interpreted according to equal standards, and if two view mammography in repeat screenings will give a better sensitivity, particularly for smaller cancers. The latter has already been shown for first screenings. 36 It is also possible to investigate a possible difference in sensitivity after first and repeat screenings by comparing the incidence of interval cancers after both screenings.
Conclusion
The stage distribution at repeat examinations in most breast cancer screening projects is less favourable than expected. Four possible explanations are presented in this paper. Two of these ("little correlation between duration of consecutive disease states" and "latent cancers") have been shown to be, at best, only part of the explanation for the discrepancy between observed and expected distributions, even when both are working together; only the "latent cancers" can be empirically investigated. A decrease in sensitivity during a screening programme seems an unlikely explanation for the discrepancy found in all the screening programmes considered in this article. The reader is urged to present other explanations, but there does seem to be a serious possibility that false reassurance has a substantial eVect on the observed stage distributions at repeat examinations, which are less favourable than expected.
